FDA advisory panels retreat from public scrutiny as controversial drug decisions mount

Advisory panels are playing a smaller public role as drug regulatory decisions grow more contentious, with a Trump-era private briefing in which an FDA official anonymously criticized UniQure’s Huntington’s disease therapy illustrating a shift toward nonpublic decision-making and sparking calls for greater transparency from patients and clinicians.